Literature DB >> 16686742

Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.

Fred Saad, Allan Lipton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16686742     DOI： 10.1111/j.1464-410X.2006.06279_7.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  2 in total

1.  Skeletal morbidity rates over time in patients with bone metastases from solid tumors reported in bone modifying agents randomised trials.

Authors:  Michael Poon; Liang Zeng; Liying Zhang; Marko Popovic; Ronald Chow; Henry Lam; Gillian Bedard; Urban Emmenegger; Christine Simmons; Edward Chow
Journal:  J Bone Oncol       Date:  2012-11-21       Impact factor: 4.072

2.  Risk factors and nomogram for newly diagnosis of bone metastasis in bladder cancer: A SEER-based study.

Authors:  Zhiyi Fan; Zhangheng Huang; Chuan Hu; Yuexin Tong; Chengliang Zhao
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.